Hvivo PLC (LON:HVO) insider Jaime Ellertson purchased 16,401 shares of Hvivo stock in a transaction dated Monday, January 8th. The stock was acquired at an average cost of GBX 55 ($0.75) per share, with a total value of £9,020.55 ($12,232.91).
Shares of Hvivo PLC (HVO) opened at GBX 50.50 ($0.68) on Friday. Hvivo PLC has a fifty-two week low of GBX 50 ($0.68) and a fifty-two week high of GBX 239.75 ($3.25). The stock has a market capitalization of $20.49 and a price-to-earnings ratio of -252.50.
Separately, Numis Securities downgraded Hvivo to a “hold” rating and set a GBX 80 ($1.08) price objective for the company. in a research note on Thursday, September 21st.
TRADEMARK VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/19/insider-buying-hvivo-plc-hvo-insider-acquires-9020-55-in-stock.html.
Hvivo Company Profile
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold.
Receive News & Ratings for Hvivo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo and related companies with MarketBeat.com's FREE daily email newsletter.